MYLAN PHARMACEUTICALS INC. v. MERCK SHARP & DOHME CORP
- CAFC Updates
- September 29, 2022
Merck owns U.S. Patent 7,326,708, which describes sitagliptin dihydrogenphosphate, a dipeptidyl peptidase-IV (“DP-IV”) inhibitor, which can be used for treating non-insulin-dependent (i.e.,...